Huntington Potter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4335549/publications.pdf

Version: 2024-02-01

56 papers

5,095 citations

304743 22 h-index 233421 45 g-index

67 all docs

67 docs citations

67 times ranked

7875 citing authors

#	Article	IF	CITATIONS
1	Proteasome activity modulates amyloid toxicity. FEMS Yeast Research, 2022, 22, .	2.3	1
2	The innate immune system stimulating cytokine GM-CSF improves learning/memory and interneuron and astrocyte brain pathology in Dp16 Down syndrome mice and improves learning/memory in wild-type mice. Neurobiology of Disease, 2022, 168, 105694.	4.4	11
3	Mild behavioral impairment as a predictor of cognitive functioning in older adults. International Psychogeriatrics, 2021, 33, 285-293.	1.0	25
4	Amylin, Al̂ ² 42, and Amyloid in Varicella Zoster Virus Vasculopathy Cerebrospinal Fluid and Infected Vascular Cells. Journal of Infectious Diseases, 2021, 223, 1284-1294.	4.0	10
5	Safety and efficacy of sargramostim (GMâ€CSF) in the treatment of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12158.	3.7	44
6	Astrogliosis and episodic memory in late life: higher GFAP is related to worse memory and white matter microstructure in healthy aging and Alzheimer's disease. Neurobiology of Aging, 2021, 103, 68-77.	3.1	31
7	Innate Immune System Activation and Neuroinflammation in Down Syndrome and Neurodegeneration: Therapeutic Targets or Partners?. Frontiers in Aging Neuroscience, 2021, 13, 718426.	3.4	17
8	Inflammation and innate immune system activation in neurodegeneration, Down syndrome, aging, and infection: Therapeutic target or partner?. Alzheimer's and Dementia, 2021, 17, .	0.8	0
9	Granulocyte-macrophage colony-stimulating factor reverses Alzheimer's disease pathology in the tgf344-AD rat model Alzheimer's and Dementia, 2021, 17 Suppl 3, e056289.	0.8	O
10	Varicella-Zoster Virus Infection of Primary Human Spinal Astrocytes Produces Intracellular Amylin, Amyloid-β, and an Amyloidogenic Extracellular Environment. Journal of Infectious Diseases, 2020, 221, 1088-1097.	4.0	25
11	Small molecule inhibitors of apolipoprotein E4â€catalyzed amyloidâ€Î² fibrillization as novel therapeutics for Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e043353.	0.8	0
12	Neuropathology and immune biomarker discovery in a rat model of Alzheimer's disease, TgF344â€AD, with controlled cortical injury model of traumatic brain injury. Alzheimer's and Dementia, 2020, 16, e046103.	0.8	0
13	Doubleâ€blind placeboâ€controlled trial of the safety and efficacy of GMâ€CSF/sargramostim in subjects with mildâ€toâ€moderate Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046497.	0.8	O
14	Role of mosaic aneuploidy in the development and progression of Huntington's disease. Alzheimer's and Dementia, 2020, 16, e047662.	0.8	0
15	Acute zoster plasma contains elevated amyloid, correlating with $A\hat{l}^2$ 42 and amylin levels, and is amyloidogenic. Journal of NeuroVirology, 2020, 26, 422-428.	2.1	9
16	Neuropsychiatric symptoms as a distinguishing factor between memory diagnoses. International Journal of Geriatric Psychiatry, 2020, 35, 1115-1122.	2.7	0
17	Further understanding the connection between Alzheimer's disease and Down syndrome. Alzheimer's and Dementia, 2020, 16, 1065-1077.	0.8	52
18	Exosome Isolation by Ultracentrifugation and Precipitation and Techniques for Downstream Analyses. Current Protocols in Cell Biology, 2020, 88, e110.	2.3	100

#	Article	IF	CITATIONS
19	Recruiting the innate immune system with GM-CSF to fight viral diseases, including West Nile Virus encephalitis and COVID-19. F1000Research, 2020, 9, 345.	1.6	8
20	Targeting the Interaction Between Apolipoprotein E and Amyloid Precursor Protein: A Novel Alzheimer's Disease Therapy. Biological Psychiatry, 2019, 86, 169-170.	1.3	2
21	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
22	Chromosome Instability and Mosaic Aneuploidy in Neurodegenerative and Neurodevelopmental Disorders. Frontiers in Genetics, 2019, 10, 1092.	2.3	32
23	Transfection by Electroporation. Current Protocols in Molecular Biology, 2018, 121, 9.3.1-9.3.13.	2.9	50
24	Mitotic defects lead to neuronal aneuploidy and apoptosis in frontotemporal lobar degeneration caused by MAPT mutations. Molecular Biology of the Cell, 2018, 29, 575-586.	2.1	36
25	Exosomal biomarkers in Down syndrome and Alzheimer's disease. Free Radical Biology and Medicine, 2018, 114, 110-121.	2.9	64
26	P1â€213: ELEVATED LEVELS OF MOSAIC ANEUPLOIDY IN HUNTINGTON'S DISEASE. Alzheimer's and Dementia, 2018, 14, P360.	0.8	1
27	P2â€162: GMâ€CSF REVERSES MEMORY DEFICITS IN THE DP16 MOUSE MODEL OF DOWN SYNDROME. Alzheimand Dementia, 2018, 14, P730.	er's 6:8	1
28	Transfection by Electroporation. Current Protocols in Immunology, 2017, 117, 10.15.1-10.15.9.	3.6	10
29	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
30	[P3–141]: FOLATE PREVENTS THE DETRIMENTAL EFFECTS OF OLIGOMERIC Aβ ON INSULIN RECEPTOR LOCALIZATION AND FUNCTION AND LONGâ€TERM POTENTIATION. Alzheimer's and Dementia, 2017, 13, P989.	0.8	1
31	[P2–140]: ABNORMAL CHROMOSOME COPY NUMBER AND ASSOCIATED NEURONAL CELL DEATH IN FRONTOTEMPORAL LOBAR DEGENERATION. Alzheimer's and Dementia, 2017, 13, P661.	0.8	O
32	[P2–143]: SCREENING FOR INHIBITORS OF APOE4 ATALYZED Aβ OLIGOMER/FILAMENT FORMATION: A NOVAPPROACH TO ALZHEIMER's DISEASE DRUG DISCOVERY. Alzheimer's and Dementia, 2017, 13, P662.	/EL 0.8	0
33	[P4–572]: INTERIM REPORT OF A PHASE 2 PILOT SAFETY AND EFFICACY TRIAL OF GMâ€CSF/LEUKINE [®] IN MILDâ€₹Oâ€MODERATE ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1572.	0.8	4
34	P2â€114: Increased Genomic Instability and Correlated Apoptosis are Associated with Cognitive Impairment in Neurodegenerative Diseases. Alzheimer's and Dementia, 2016, 12, P655.	0.8	0
35	Inhibition of the Motor Protein Eg5/Kinesin-5 in Amyloid $\langle i \rangle \hat{l}^2 \langle i \rangle$ -Mediated Impairment of Hippocampal Long-Term Potentiation and Dendritic Spine Loss. Molecular Pharmacology, 2016, 89, 552-559.	2.3	22
36	Down syndrome and Alzheimer's disease: Common pathways, commonÂgoals. Alzheimer's and Dementia, 2015, 11, 700-709.	0.8	218

#	Article	IF	CITATIONS
37	Kinesin light chainâ \in 1 variant E disrupts axonal transport and AÎ ² generation in Alzheimer's disease (comment on DOI 10.1002/bies.201400131). BioEssays, 2015, 37, 118-118.	2.5	0
38	Alzheimer amyloid beta inhibition of Eg5/kinesin 5 reduces neurotrophin and/or transmitter receptor function. Neurobiology of Aging, 2014, 35, 1839-1849.	3.1	35
39	David H. Dressler 1941–2014. Nature Genetics, 2014, 46, 1044-1044.	21.4	1
40	USE OF FUSED CIRCULATIONS TO INVESTIGATE THE ROLE OF APOLIPOPROTEIN E AS AMYLOID CATALYST AND PERIPHERAL SINK IN ALZHEIMER'S DISEASE. Technology and Innovation, 2012, 14, 199-208.	0.2	10
41	Apolipoprotein E: Essential Catalyst of the Alzheimer Amyloid Cascade. International Journal of Alzheimer's Disease, 2012, 2012, 1-9.	2.0	67
42	Granulocyte Macrophage Colony Stimulating Factor Treatment is Associated with Improved Cognition in Cancer Patients. Brain Disorders & Therapy, 2012, 01, .	0.1	19
43	GM-CSF Upregulated in Rheumatoid Arthritis Reverses Cognitive Impairment and Amyloidosis in Alzheimer Mice. Journal of Alzheimer's Disease, 2010, 21, 507-518.	2.6	101
44	Age related changes in clonalities of T cell Age –related changes in clonalities of T cell receptor Vβ repertoire within CD8 subsets, but not CD4 in healthy individuals. FASEB Journal, 2008, 22, 375-375.	0.5	0
45	Transfection by Electroporation. Current Protocols in Molecular Biology, 2003, 62, Unit 9.3.	2.9	52
46	Transfection by Electroporation. Current Protocols in Cell Biology, 2003, 19, Unit 20.5.	2.3	2
47	The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiology of Aging, 2001, 22, 923-930.	3.1	79
48	The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer s disease. Frontiers in Bioscience - Landmark, 1998, 3, d436-446.	3.0	25
49	Transfection by Electroporation. Current Protocols in Neuroscience, 1997, 1, A.1E.1-A.1E.5.	2.6	4
50	Alzheimer Aβ neurotoxicity: Promotion by antichymotrypsin, ApoE4; inhibition by Aβ-related peptides. Neurobiology of Aging, 1996, 17, 773-780.	3.1	105
51	Amyloid-associated proteins $\hat{l}\pm 1$ -antichymotrypsin and apolipoprotein E promote assembly of Alzheimer \hat{l}^2 -protein into filaments. Nature, 1994, 372, 92-94.	27.8	909
52	Identification of a Chymotrypsinâ€Like Mast Cell Protease in Rat Brain Capable of Generating the Nâ€Terminus of the Alzheimer Amyloid βâ€Protein. Journal of Neurochemistry, 1993, 61, 567-577.	3.9	41
53	Transfection by Electroporation. Current Protocols in Immunology, 1992, 3, Unit 10.15.	3.6	2
54	Transfection by Electroporation. Current Protocols in Molecular Biology, 1991, 14, 9.3.1-9.3.4.	2.9	1

Huntington Potter

#	Article	IF	CITATIONS
55	The Protease Inhibitor, α1-Antichymotrypsin, Is a Component of the Brain Amyloid Deposits in Normal Aging and Alzheimer's Disease. Annals of Medicine, 1989, 21, 77-81.	3.8	33
56	Alzheimer's Disease: Recent Advances in Understanding the Brain Amyloid Deposits. Nature Biotechnology, 1989, 7, 147-153.	17. 5	36